Literature DB >> 29191619

Lung Cancer Screening in the Post-National Lung Screening Trial Era: Applying Screening in the Real World.

Simon R Turner1, James M Isbell2.   

Abstract

The National Lung Screening Trial established a survival benefit for lung cancer screening using low-dose computed tomography. In the wake of this trial several international bodies now recommend lung cancer screening. However, three main questions remain unanswered: Who is the optimal population for screening? How often should they be screened? For how long should screening be continued? We examine the results of the available randomized trials to address these questions.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  National Lung Screening Trial; low-dose computed tomography; lung cancer; screening

Year:  2017        PMID: 29191619      PMCID: PMC5971130          DOI: 10.1053/j.semtcvs.2017.11.008

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  18 in total

1.  Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial.

Authors:  Nanda Horeweg; Carlijn M van der Aalst; Rozemarijn Vliegenthart; Yingru Zhao; Xueqian Xie; Ernst Th Scholten; Willem Mali; Erik Thunnissen; Carla Weenink; Harry J M Groen; Jan-Willem J Lammers; Kristiaan Nackaerts; Joost van Rosmalen; Matthijs Oudkerk; Harry J de Koning
Journal:  Eur Respir J       Date:  2013-07-11       Impact factor: 16.671

2.  Lung Cancer Risk and Demographic Characteristics of Current 20-29 Pack-year Smokers: Implications for Screening.

Authors:  Paul F Pinsky; Barnett S Kramer
Journal:  J Natl Cancer Inst       Date:  2015-10-19       Impact factor: 13.506

3.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

4.  Low-dose computed tomography for lung cancer screening: comparison of performance between annual and biennial screen.

Authors:  Nicola Sverzellati; M Silva; G Calareso; C Galeone; A Marchianò; S Sestini; G Sozzi; U Pastorino
Journal:  Eur Radiol       Date:  2016-02-11       Impact factor: 5.315

5.  The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.

Authors:  J K Gohagan; P C Prorok; R B Hayes; B S Kramer
Journal:  Control Clin Trials       Date:  2000-12

6.  Selection criteria for lung-cancer screening.

Authors:  Martin C Tammemägi; Hormuzd A Katki; William G Hocking; Timothy R Church; Neil Caporaso; Paul A Kvale; Anil K Chaturvedi; Gerard A Silvestri; Tom L Riley; John Commins; Christine D Berg
Journal:  N Engl J Med       Date:  2013-02-21       Impact factor: 91.245

7.  Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval.

Authors:  Uraujh Yousaf-Khan; Carlijn van der Aalst; Pim A de Jong; Marjolein Heuvelmans; Ernst Scholten; Jan-Willem Lammers; Peter van Ooijen; Kristiaan Nackaerts; Carla Weenink; Harry Groen; Rozemarijn Vliegenthart; Kevin Ten Haaf; Matthijs Oudkerk; Harry de Koning
Journal:  Thorax       Date:  2016-06-30       Impact factor: 9.139

8.  Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening.

Authors:  Nanda Horeweg; Joost van Rosmalen; Marjolein A Heuvelmans; Carlijn M van der Aalst; Rozemarijn Vliegenthart; Ernst Th Scholten; Kevin ten Haaf; Kristiaan Nackaerts; Jan-Willem J Lammers; Carla Weenink; Harry J Groen; Peter van Ooijen; Pim A de Jong; Geertruida H de Bock; Willem Mali; Harry J de Koning; Matthijs Oudkerk
Journal:  Lancet Oncol       Date:  2014-10-01       Impact factor: 41.316

9.  Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

10.  ESR/ERS white paper on lung cancer screening.

Authors:  Hans-Ulrich Kauczor; Lorenzo Bonomo; Mina Gaga; Kristiaan Nackaerts; Nir Peled; Mathias Prokop; Martine Remy-Jardin; Oyunbileg von Stackelberg; Jean-Paul Sculier
Journal:  Eur Respir J       Date:  2015-04-30       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.